Designation of Mercaptamine Hydrochloride (Cystadrops) as an orphan drug - Emerge Health Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate therapeutic goods in Australia, ensuring their safety, quality, and efficacy. This legislation was introduced to address the need for a comprehensive regulatory framework governing the importation, supply, and use of therapeutic goods, including medicines, medical devices, and other health-related products. The Act is overseen by the Therapeutic Goods Administration, which is a part of the Commonwealth of Australia's Department of Health. The policy objective of the Act is to protect public health by ensuring that therapeutic goods available in Australia meet the necessary standards for safety, quality, and efficacy. The designation of Mercaptamine Hydrochloride (CYSTADROPS) as an orphan drug under the Act highlights the commitment to addressing rare medical conditions by facilitating the development and availability of treatments for such conditions.

Scope and Application

The Therapeutic Goods Act 1989 applies to the regulation of therapeutic goods in Australia, ensuring that these products are safe, of high quality, and effective for their intended use. The Act, administered by the Therapeutic Goods Administration (TGA), has a broad scope and applies to a wide range of products, including medicines, medical devices, and other health-related goods. It governs the manufacture, importation, supply, and advertising of these goods, ensuring compliance with stringent standards. The Act applies to all persons and entities involved in the supply chain of therapeutic goods, including manufacturers, importers, and healthcare providers. Geographically, the Act has national jurisdiction, covering the entire Commonwealth of Australia. Specific exclusions and exemptions may apply, often detailed in subordinate instruments or regulations, which provide further clarification on the scope and specific requirements of the Act. The Act also enables the designation of certain drugs, such as Mercaptamine Hydrochloride (CYSTADROPS) in this instance, as orphan drugs to encourage the development of treatments for rare conditions.

Key Provisions

Pursuant to the Therapeutic Goods Act 1989, the Therapeutic Goods Administration (TGA) has designated Mercaptamine Hydrochloride (CYSTADROPS) as an orphan drug under section 16J of the Therapeutic Goods Regulations 1990. This designation, effective from 17 July 2015, acknowledges the drug’s intended use for the treatment of corneal cystine deposits in cystinosis, a rare condition affecting both adults and children over two years of age. The therapeutic form in question is an eye drops solution. This specific designation is crucial as it recognises the rarity of the condition and the necessity of developing treatments that would otherwise not be commercially viable. Under this legislation, the obligations for Emerge Health Pty Ltd, the sponsor of Mercaptamine Hydrochloride (CYSTADROPS), include ensuring the drug’s safety, efficacy, and quality meet the standards set forth by the TGA. As the sponsor, Emerge Health Pty Ltd must comply with all requirements related to the clinical trial, manufacturing, and marketing of the orphan drug. This encompasses detailed record-keeping, adherence to good manufacturing practices, and submission of necessary documentation to the TGA. Furthermore, the sponsor must ensure that any claims made about the drug are substantiated and that adverse events are reported promptly. Breaches of the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 can result in significant consequences. For example, misleading or false representations about the therapeutic goods can lead to civil penalties. According to the Act, individuals or entities found guilty of such offences may face fines up to $222,200 for a corporation and $44,440 for an individual. Additionally, criminal penalties may apply, with potential imprisonment for up to five years. These stringent measures underscore the importance of compliance with the regulations to ensure public health and safety are not compromised.